The new nonprescription tablet pairs acetaminophen and naproxen sodium for 12-hour pain relief — the first fixed-dose combo of the two sold over the counter.
Edinburgh and Bristol researchers traced disc degeneration to a collagen defect and mineral buildup — and found existing drugs could slow it, hinting at alternatives to surgery.
The structured financing releases cash as seralutinib hits regulatory milestones, funding the biotech through a planned NDA submission for pulmonary hypertension.
Kindred Companion Sciences edited a single gene to knock out Can f 1, the protein behind most dog allergies — and says two edited beagles are healthy at nearly two years old.
The CRISPR biotech, which silences genes without cutting DNA, priced a modest offering in a cautious market — a notable reopening for gene-editing listings.
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.
The deal adds gildeuretinol, a modified vitamin A in Phase 3 for Stargardt disease, to Tarsus — a program championed by Vertex founder Josh Boger.
Vanderbilt researchers created the first compounds to selectively switch a protein family called TAOK on or off — research tools, not drugs, that could open new Alzheimer’s leads.
Vertex raised guidance on $3.2B in quarterly CF sales, yet analysts are watching tiny Sionna Therapeutics, whose experimental drug could layer on top of Vertex’s Trikafta.
In a six-year study of older adults, having both abdominal obesity and low vitamin D was tied to more than double the risk of death — each condition amplifying the other.
The Nav1.8-inhibitor developer priced at the top of its range to fund a Phase 3-ready pain drug meant to rival Vertex’s Journavx, as biotech IPOs keep rolling.
Backed by Bezos and Gates funds, the company’s fungal-genome platform yielded LIFE-001, a long-acting drug that suppresses transplant rejection while sparing the brain.